Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $2.89M rose 28.5% year over year, ahead of the +16.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 22.0% from the prior quarter. Over 3 fiscal years it compounded at +27.2% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, down 0.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.5% holds above the trailing-twelve-month pace of +16.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 9.06M USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- +230.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.06M | +13.9% |
| FY2024 | 2024-12-31 | 7.96M | +16.4% |
| FY2023 | 2023-12-31 | 6.83M | +55.2% |
| FY2022 | 2022-12-31 | 4.4M | +5692.1% |
| FY2021 | 2021-12-31 | 76K | — |
Depreciation & Amortization vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's LTM Jun 2026 depreciation & amortization of $9.94M is the 5th highest of the 11 companies compared; the peer median is $1.66M.
- Its year-over-year change of +16.8% is the 4th highest of 10, against a peer median of -9.6%.
- Depreciation & amortization amounts to 1.3% of revenue for AXSM, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $539.67M | -21.3% | +3.4% | 11.4% | |
| LTM Jun 2026 | $101.71M | +26.1% | +2.3% | 12.2% | |
| LTM Sep 2026 | $39.6M | +33.3% | +24.5% | 1.1% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $9.94M | +16.8% | +27.2% | 1.3% | |
| LTM Sep 2026 | $2.32M | -9.6% | +21.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +307.8% | 5.0% |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $631K | -13.8% | — | — |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding AXSM) | $1.66M | -9.6% | +8.0% | 11.4% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 50.04M | 270.6M | 385.69M | 638.5M |
| Cost of Revenue | 0 | 5.2M | 26.07M | 33.3M | 47.48M |
| Gross Profit | 0 | 44.84M | 244.54M | 352.39M | 591.02M |
| Gross Margin | — | 89.6% | 90.4% | 91.4% | 92.6% |
| Research & Development | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
| Selling, General & Admin | 66.65M | 159.25M | 323.12M | 411.36M | 570.6M |
| Operating Expenses | 124.71M | 224.64M | 476.36M | 632.95M | 760.25M |
| Depreciation & Amortization | 76K | 4.4M | 6.83M | 7.96M | 9.06M |
| EBITDA | (124.63M) | (175.4M) | (224.99M) | (272.6M) | (168.08M) |
| EBITDA Margin | — | -350.5% | -83.1% | -70.7% | -26.3% |
| Operating Income | (124.71M) | (179.8M) | (231.83M) | (280.56M) | (169.24M) |
| Operating Margin | — | -359.3% | -85.7% | -72.7% | -26.5% |
| Interest Income | 0 | 0 | 0 | 0 | 9.37M |
| Interest Expense | 5.7M | 7.34M | 6.45M | 6.57M | 6.56M |
| Other Income / Expenses | (5.7M) | (7.34M) | (6.45M) | (6.57M) | (14.47M) |
| Income Before Tax | (130.4M) | (187.13M) | (238.28M) | (287.13M) | (183.7M) |
| Pre-Tax Margin | — | -374.0% | -88.1% | -74.4% | -28.8% |
| Income Tax Expense | 0 | 0 | 960K | 85K | (530K) |
| Net Income | (130.4M) | (187.13M) | (239.24M) | (287.22M) | (183.17M) |
| Net Margin | — | -374.0% | -88.4% | -74.5% | -28.7% |
| EPS (Basic) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| EPS (Diluted) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| Weighted Avg Shares | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
| Weighted Avg Shares (Diluted) | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.